Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
H2AFX
REST API REST API
Homo sapiens
H2AFX is differentially expressed in 322 experiments: 128 organism parts: bone marrow, thymus, ... (126 more);, 238 disease states: normal, lung adenocarcinoma, ... (236 more);, 101 cell types 406 cell lines 42 compound treatments and 81 other conditions.
Synonyms H2AX
Orthologs H2afx (Mus musculus)   zgc:114037 (Danio rerio)   zgc:195633 (Danio rerio)   zgc:114037 (Danio rerio)   zgc:195633 (Danio rerio)   CR354435.5 (Danio rerio)   CR762436.3 (Danio rerio)   zgc:110434 (Danio rerio)   zgc:195633 (Danio rerio)   FP236812.1 (Danio rerio)   CR762436.4 (Danio rerio)   FP236812.2 (Danio rerio)   FP325123.2 (Danio rerio)   CU457819.2 (Danio rerio)   zgc:114037 (Danio rerio)   FP236812.4 (Danio rerio)   CR354435.7 (Danio rerio)   zgc:195633 (Danio rerio)   zgc:101846 (Danio rerio)   CU302436.2 (Danio rerio)   Q17QG8_BOVIN (Bos taurus)   H2afx (Rattus norvegicus)   His2A:CG33820 (Drosophila melanogaster)   His2A:CG33823 (Drosophila melanogaster)   His2A:CG33826 (Drosophila melanogaster)   His2A:CG33829 (Drosophila melanogaster)   His2A:CG33814 (Drosophila melanogaster)   His2A:CG33817 (Drosophila melanogaster)   His2A:CG33808 (Drosophila melanogaster)   His2A:CG33835 (Drosophila melanogaster)   His2A:CG33832 (Drosophila melanogaster)   His2A:CG31618 (Drosophila melanogaster)   His2A:CG33841 (Drosophila melanogaster)   His2A:CG33838 (Drosophila melanogaster)   zgc:163047 (Danio rerio)   H2AFX (Canis familiaris)   zgc:114037 (Danio rerio)   (Compare orthologs)
Gene Ontology Term chromosome, telomeric region, condensed nuclear chromosome, DNA damage checkpoint, DNA binding, double-strand break repair via homologous recombination, protein binding, DNA repair, nuclear chromatin, histone binding, damaged DNA binding, intracellular, meiosis, male germ cell nucleus, replication fork, spermatogenesis, double-strand break repair, sequence-specific DNA binding, response to ionizing radiation, cell cycle, nucleus, DNA recombination, nucleosome, chromosome, chromatin, nucleoplasm, response to DNA damage stimulus, enzyme binding, nucleosome assembly, XY body, positive regulation of DNA repair
InterPro Term CBFA_NFYB_domain, Histone_core_D, Histone_H2A
UniProt Accession P16104
Search EB-eye ENSG00000188486
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-15765, E-GEOD-6573, E-GEOD-1577, E-MEXP-433, ... (31 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-19639, E-GEOD-18005, E-GEOD-19397, ... (41 experiments)

Factor Value U/D Experiments
MCF-7
4
E-GEOD-19639, E-GEOD-20081, E-GEOD-5823, E-GEOD-3529
HepG2
2
E-MTAB-37, E-GEOD-21154
BT20
2
E-MTAB-62, E-MTAB-37
KG1
2
E-MTAB-37, E-GEOD-24147
MOLT4
2
E-MTAB-37, E-MTAB-62
SW480
2
E-MTAB-37, E-GEOD-18005
400 more value(s).


Cell type

studied in E-GEOD-22373, E-GEOD-3920, E-MEXP-750, E-MEXP-66, E-GEOD-4219, ... (48 experiments)

Factor Value U/D Experiments
2
2
E-TABM-145, E-TABM-130
721 B lymphoblast
2
E-AFMX-5, E-TABM-145
CD8+ T cell
2
E-AFMX-5, E-GEOD-6740
centroblast
2
E-GEOD-15271, E-TABM-702
fibroblast
2
E-GEOD-3204, E-GEOD-3920
SVG-A
1
E-GEOD-7819
95 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-2466, E-GEOD-1577, E-TABM-15, ... (66 experiments)

Factor Value U/D Experiments
lung adenocarcinoma
4
E-GEOD-2514, E-MTAB-37, E-MTAB-62, E-MEXP-231
acute lymphoblastic leukemia
3
E-MTAB-37, E-MTAB-62, E-GEOD-96
colon carcinoma
3
E-MTAB-62, E-GEOD-3726, E-MTAB-57
control
3
E-GEOD-16363, E-GEOD-21912, E-GEOD-20602
glioblastoma
3
E-GEOD-6014, E-GEOD-4290, E-MTAB-62
gastric carcinoma
2
E-GEOD-2685, E-MTAB-37
232 more value(s).


Compound treatment

studied in E-GEOD-1417, E-TABM-782, E-GEOD-5824, E-MEXP-1958, E-MEXP-2590, ... (28 experiments)

Factor Value U/D Experiments
TGF-Beta1
1
E-MEXP-2645
5-aza-2'-deoxycytidine + trichostatin A
1
1
E-MEXP-1269
NaOH
1
E-MEXP-2590
Cxcl12
1
E-GEOD-7307
vanadium pentoxide
1
E-GEOD-5339
HMB-PP (phosphoantigen)
1
1
E-MEXP-1601
36 more value(s).


Age at diagnosis

studied in E-GEOD-4922

Factor Value U/D Experiments
53 years
1
1
E-GEOD-4922


Agent
studied in E-GEOD-19519

Biosource provider
studied in E-MTAB-37

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd1a
studied in E-GEOD-22601

cd3
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Chromosomal aberration
studied in E-TABM-125

Clinical history
studied in E-GEOD-19743, E-GEOD-7967, E-TABM-125, E-GEOD-21374, E-GEOD-21589, ... (7 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-6710, E-MEXP-1251, E-GEOD-2034, ... (8 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-19743, E-GEOD-5999, E-GEOD-1614, E-GEOD-20033, E-MEXP-2359, ... (7 experiments)

Disease staging
studied in E-GEOD-1323, E-GEOD-19743, E-GEOD-3325, E-TABM-147, E-GEOD-21138, ... (7 experiments)

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518, E-GEOD-4086

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-3494, E-GEOD-6532, E-GEOD-4922

Ethnic group
studied in E-GEOD-1643, E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-GEOD-4025, E-MEXP-1482, E-GEOD-7578, E-GEOD-17385, E-GEOD-20847, ... (8 experiments)

Genotype
studied in E-GEOD-1923, E-GEOD-3494, E-GEOD-2466, E-GEOD-17476, E-GEOD-22593, ... (12 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-5681, E-GEOD-7011, E-GEOD-10315, E-TABM-440, E-GEOD-837, ... (15 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-276, E-GEOD-20194, E-GEOD-16716, E-GEOD-2748 ... (5 experiments)

Individual
studied in E-TABM-325, E-MTAB-197, E-GEOD-2466, E-MEXP-2069, E-GEOD-1926, ... (33 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-12108, E-GEOD-12254, E-GEOD-9723, E-MEXP-561, ... (6 experiments)

Injury
studied in E-GEOD-19743

Irradiate
studied in E-GEOD-1977, E-MEXP-2177

Ki67 ihc
studied in E-GEOD-21653

Labeling
studied in E-LGCL-5

Light
studied in E-GEOD-1725

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

Observation
studied in E-TABM-276

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-7540, E-AFMX-1, E-GEOD-426

Organism status
studied in E-GEOD-19188

Original diagnosis
studied in E-GEOD-21521

P53 ihc
studied in E-GEOD-21653

Pcr vs rd
studied in E-GEOD-20194, E-GEOD-16716

Performer
studied in E-LGCL-5

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-7819, E-GEOD-4525, E-GEOD-19703, E-GEOD-1309, E-GEOD-21750, ... (10 experiments)

Population
studied in E-MTAB-197, E-GEOD-4922

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532

Protocol type
studied in E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246

Replicate
studied in E-GEOD-18791, E-GEOD-10896

RNAi
studied in E-MEXP-2115, E-GEOD-12438, E-MEXP-1509, E-MEXP-548, E-GEOD-3697, ... (7 experiments)

Sample preparation
studied in E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-21374, E-MEXP-70, E-GEOD-17400, E-GEOD-18995 ... (5 experiments)

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-1643, E-GEOD-2466, E-GEOD-7307, E-GEOD-16363, E-GEOD-1295 ... (5 experiments)

Stimulation
studied in E-GEOD-4883, E-GEOD-20114, E-GEOD-11886, E-GEOD-11428

Strain or line
studied in E-TABM-125

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

targeted_cell_type
studied in E-MEXP-70

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-GEOD-1926, E-TABM-276, E-GEOD-2748

Treatment
studied in E-GEOD-16837, E-MEXP-973, E-GEOD-19246, E-GEOD-13818, E-GEOD-19815, ... (7 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-89, E-GEOD-4290, E-GEOD-3494, E-GEOD-22541, E-TABM-43, ... (7 experiments)

Vehicle
studied in E-GEOD-5258

Processing time: 0.353 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM